Charles River takeover of WuXi collapses

Charles River bows to shareholder pressure and abandons its $1.6 billion takeover of WuXi PharmaTech, signalling that Western buyers may find it difficult to garner the support they need to strike deals in Asia's fast-growing economies.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition